These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30548024)

  • 21. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
    Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
    HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
    [No Abstract]   [Full Text] [Related]  

  • 24. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.
    Blair HA
    Drugs; 2018 Nov; 78(16):1741-1750. PubMed ID: 30406902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
    Capetti AF; Cossu MV; Paladini L; Rizzardini G
    Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
    Gatell JM; Assoumou L; Moyle G; Waters L; Johnson M; Domingo P; Fox J; Martinez E; Stellbrink HJ; Guaraldi G; Masia M; Gompels M; De Wit S; Florence E; Esser S; Raffi F; Stephan C; Rockstroh J; Giacomelli A; Vera J; Bernardino JI; Winston A; Saumoy M; Gras J; Katlama C; Pozniak AL;
    Clin Infect Dis; 2019 Feb; 68(4):597-606. PubMed ID: 29912307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
    Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
    HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
    J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
    HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
    Mehta R; Lagishetty CV; Angelis K; Aylott A; Kahl L; Blair L; Matthews J; Wynne B; Crauwels H; Underwood M; Adkison KK
    Br J Clin Pharmacol; 2023 Jul; 89(7):2190-2200. PubMed ID: 36740580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
    Gatell JM; Assoumou L; Moyle G; Waters L; Johnson M; Domingo P; Fox J; Martinez E; Stellbrink HJ; Guaraldi G; Masia M; Gompels M; De Wit S; Florence E; Esser S; Raffi F; Pozniak AL;
    AIDS; 2017 Nov; 31(18):2503-2514. PubMed ID: 29112070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
    Capetti AF; Cossu MV; Sterrantino G; Barbarini G; Di Giambenedetto S; De Socio GV; Orofino G; Di Biagio A; Celesia BM; Rusconi S; Argenteri B; Rizzardini G
    Ann Pharmacother; 2018 Aug; 52(8):740-746. PubMed ID: 29482352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
    Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
    Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.
    Yendewa GA; Salata RA
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
    Capetti AF; Astuti N; Cattaneo D; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
    McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
    Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
    HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.